Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor in lung cancer

Mutant selective epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), such as rociletinib and AZD9291, are effective for tumors with T790M secondary mutation that become refractory to first‐generation EGFR‐TKI. However, acquired resistance to these prospective drugs is anticipate...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuuchi, Hiroshi, Suda, Kenichi, Murakami, Isao, Sakai, Kazuko, Sato, Katsuaki, Kobayashi, Yoshihisa, Shimoji, Masaki, Chiba, Masato, Sesumi, Yuichi, Tomizawa, Kenji, Takemoto, Toshiki, Sekido, Yoshitaka, Nishio, Kazuto, Mitsudomi, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832847/
https://www.ncbi.nlm.nih.gov/pubmed/26845230
http://dx.doi.org/10.1111/cas.12905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832847/
https://www.ncbi.nlm.nih.gov/pubmed/26845230
http://dx.doi.org/10.1111/cas.12905

Ejemplares similares